LECAP Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

LECAP Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$673K	Buy	1,507 +262	+21%	+$122K	0.25%	161
2025 Q4	$564K	Buy	+1,245	New	+$537K	0.22%	163
2025 Q1	–	Sell	-1,944	Closed	-$783K	–	399
2024 Q4	$783K	Buy	+1,944	New	+$901K	0.21%	172
2024 Q3	–	Sell	-2,449	Closed	-$1.15M	–	422
2024 Q2	$1.15M	Sell	2,449 -330	-12%	-$143K	0.25%	160
2024 Q1	$1.16M	Buy	+2,779	New	+$1.17M	0.24%	160

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LECAP Asset Management's VRTX Position: Q1 2026 in Review

LECAP Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q1 2026, buying an estimated $122K and bringing the position to 1,507 shares worth $673K. The position accounts for 0.25% of the portfolio, ranked #161.

LECAP Asset Management first reported a position in VRTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $1.16M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

LECAP Asset Management held 1,507 shares of Vertex Pharmaceuticals worth $673K as of Q1 2026.
LECAP Asset Management bought 262 Vertex Pharmaceuticals shares in Q1 2026, an estimated $122K.
Vertex Pharmaceuticals made up 0.25% of LECAP Asset Management's portfolio in Q1 2026, its #161 holding.
LECAP Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
LECAP Asset Management's Vertex Pharmaceuticals position peaked at $1.16M in Q1 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on LECAP Asset Management's 13F filing for Q1 2026, filed 30 Apr 2026.